RxDoctor Payments Data

Sabitha Pabbathi, MD

Internal Medicine · Bakersfield, CANPI 1477744498

Payments from drug & device makers

$2,077in general payments, 2019–2025

Across 127 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$408
  • Amgen$382
  • Lilly USA, LLC$247
  • Gilead$156
  • Novo Nordisk$146
  • AbbVie$97
  • plus $640 from 13 others

What the payments were for

  • Food & beverage$2,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,077 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$892
Medicare patients
29
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$110,451
OzempicSemaglutide92$86,811
TradjentaLinagliptin65$44,583
RybelsusSemaglutide23$25,710
TrulicityDulaglutide12$15,103
EliquisApixaban24$14,621
MounjaroTirzepatide12$12,335
FarxigaDapagliflozin Propanediol21$12,302
Combivent RespimatIpratropium/Albuterol Sulfate11$5,353
Tresiba Flextouch U-100Insulin Degludec14$5,314
Xigduo XrDapaglifloz Propaned/Metformin11$4,539
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,750
Albuterol Sulfate HfaAlbuterol Sulfate152$3,554
Qvar RedihalerBeclomethasone Dipropionate16$3,456
SymbicortBudesonide/Formoterol Fumarate12$2,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$146$112,521115 claims
Lilly USA, LLCTrulicity, Mounjaro$247$27,43824 claims
AstraZenecaFarxiga, Symbicort$62$14,83833 claims
PfizerEliquis$47$14,62124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →